Pioglitazone
Links shared publicly online about this topic
Family Medicine Article | Pioglitazone
mdlinx.com — “Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects” View full resource at mdlinx.com
Most Recently Shared on March 24, 2011 at 4:40 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects: Athe... http://bit.ly/fzauC8 #FamPractice
Pioglitazone slows progression of carotid atherosclerosis
theheart.org — “Carotid artery intima media thickness was 38% lower in subjects taking pioglitazone compared with those taking placebo in the diabetes-prevention trial ACTOS Now.” View full resource at theheart.org
Most Recently Shared on June 9, 2009 at 7:33 pm By:
heartwire: Pioglitazone slows progression of carotid atherosclerosis http://bit.ly/iK5Yq
Pulse - Experts advise pioglitazone switch
pulsetoday.co.uk — “Pulse - Experts advise pioglitazone switch” View full resource at pulsetoday.co.uk
Most Recently Shared on September 27, 2010 at 1:13 pm By:
PulseToday Health News and Medical Publisher
Experts advise pioglitazone switch: GPs reviewing patients on rosiglitazone should consider switching them straigh... http://bit.ly/cy538l
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone)
medicalnewstoday.com — “The U.S. Food and Drug Administration announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study des” View full resource at medicalnewstoday.com
Most Recently Shared on September 18, 2010 at 2:05 pm By:
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone) http://mnt.to/3K23 #diabetes
Insulin combined with pioglitazone: risk of cardiac failure : MHRA
mhra.gov.uk — “Insulin combined with pioglitazone: risk of cardiac failure : MHRA” View full resource at mhra.gov.uk
Most Recently Shared on January 17, 2011 at 8:57 pm By:
Insulin combined with pioglitazone: risk of cardiac failure (MHRA) http://bit.ly/fl22d1
Study: Pioglitazone halts progression to type 2 diabetes
endocrinetoday.com — “In a new study, pioglitazone reduced the risk for progression from impaired glucose tolerance to type 2 diabetes by 72% as compared with placebo” View full resource at endocrinetoday.com
Most Recently Shared on March 24, 2011 at 4:42 pm By:
Study: Pioglitazone halts progression to type 2 diabetes http://bit.ly/eSsoun
Pioglitazone delayed atheroma progression in patients with diabetes
endocrinetoday.com — “Patients with type 2 diabetes who were treated with pioglitazone experienced improvements in triglyceride/HDL ratio that were associated with de” View full resource at endocrinetoday.com
Most Recently Shared on January 7, 2011 at 4:14 pm By:
#Pioglitazone delayed #atheroma progression in patients with #diabetes http://bit.ly/dH21XZ
June 28 JAMA article comparing rosiglitazone to pioglitazone
newsroom.heart.org — “AHA Newsroom” View full resource at newsroom.heart.org
Most Recently Shared on June 28, 2010 at 3:06 pm By:
June 28 JAMA article comparing rosiglitazone to pioglitazone: American Heart Association Comment http://bit.ly/csghm6
Investigators study Pioglitazone and Vitamin E for treatment of NASH
news-medical.net — “A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.” View full resource at news-medical.net
Most Recently Shared on April 29, 2010 at 6:36 am By:
Obesity News: Investigators study Pioglitazone and Vitamin E for treatment of NASH: A daily dose of a specific f... http://twurl.nl/7khdyx
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone)
diabetesincontrol.com — “Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.” View full resource at diabetesincontrol.com
Most Recently Shared on September 30, 2010 at 3:46 pm By:
AmDiabetesAssn Health Organization
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone) http://t.co/owEq4cN via @AddThis
NEJM -- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
content.nejm.org — “Original Article from The New England Journal of Medicine -- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis” View full resource at content.nejm.org
Most Recently Shared on April 30, 2010 at 8:07 pm By:
Evelyn Tribole Nutritionist, Dietitian, and Active Health Library
Vitamin E shown to be effective for fatty liver disease, says NEJM study. Free full text http://bit.ly/dwGh0R
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer
fda.gov — “FDA reviewing preliminary results on five-year data from an ongoing, 10-year observational epidemiological study.” View full resource at fda.gov
Most Recently Shared on September 17, 2010 at 7:53 pm By:
madan kwatra PhD and Doctor
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer http://t.co/EwWFq9h
Once-weekly exenatide vs daily sitagliptin or pioglitazone
theheart.org — “The investigational glucagonlike peptide-1 receptor agonist exenatide lowers hemoglobin A1C levels to a greater extent; more patients with type 2 diabetes reached A1C targets.” View full resource at theheart.org
Most Recently Shared on June 9, 2009 at 6:28 pm By:
heartwire: Once-weekly exenatide achieves better glycemic control than daily sitagliptin or pioglitazone http://bit.ly/10diDq
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer
fda.gov — “FDA reviewing preliminary results on five-year data from an ongoing, 10-year observational epidemiological study.” View full resource at fda.gov
Most Recently Shared on February 21, 2011 at 8:40 pm By:
madan kwatra PhD and Doctor
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer http://t.co/8p9B2IZ via @AddThis
ACP Hospitalist, September 2011 - Rivaroxaban approved, warning issued on pioglitazone
acphospitalist.org — “ACP Hospitalist, September 2011 - Rivaroxaban approved, warning issued on pioglitazone” View full resource at acphospitalist.org
Most Recently Shared on September 23, 2011 at 12:00 pm By:
ACP Hospitalist Medical Journal
Rivaroxaban approved, warning issued on pioglitazone and bladder cancer http://ow.ly/6y8Rt
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
PulseToday
PulseToday.co.uk - Medical news, views, education and clinical information to GPs, nurses and other health professionals.
Advertisement
